2020
Release time：2020-02-17 15:51
GT1708F Obtains Approval of Clinical Trial from FDA
Kintor Pharmaceutical’s Suzhou Industrialisation Base Granted Approval of Pharmaceutical Production License
New Start For New Journey! Kintor Relocated To Suzhou R&D Center And Industrialization Base
Proxalutamide Starts Clinical Trial For The Treatment Of COVID-19 In Male Patients
Kintor Pharma Signed Clinical Trial Agreement For The Treatment Of COVID-19 With Proxalutamide
Officially listed on the Hong Kong Stock Exchange (Stock Code:9939.HK)
Kintor pharmaceutical and Sinopharm signed a strategic cooperation agreement
The GT1708F project has been approved for clinical trials in China
recommend News
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn